Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression
Author: Ahn, Y.
Gibbons, D.
Chakravarti, D.
Creighton, C.
Rizvi, Z.
Adams, H.
Pertsemlidis, A.
Gregory, P.
Wright, J.
Goodall, G.
Flores, E.
Kurie, J.
Citation: Journal of Clinical Investigation, 2012; 122(9):3170-3183
Publisher: Amer Soc Clinical Investigation Inc
Issue Date: 2012
ISSN: 0021-9738
Statement of
Young-Ho Ahn, Don L. Gibbons, Deepavali Chakravarti, Chad J. Creighton, Zain H. Rizvi, Henry P. Adams, Alexander Pertsemlidis, Philip A. Gregory, Josephine A. Wright, Gregory J. Goodall, Elsa R. Flores and Jonathan M. Kurie
Abstract: Metastatic cancer is extremely difficult to treat, and the presence of metastases greatly reduces a cancer patient’s likelihood of long-term survival. The ZEB1 transcriptional repressor promotes metastasis through downregulation of microRNAs (miRs) that are strong inducers of epithelial differentiation and inhibitors of stem cell factors. Given that each miR can target multiple genes with diverse functions, we posited that the prometastatic network controlled by ZEB1 extends beyond these processes. We tested this hypothesis using a mouse model of human lung adenocarcinoma metastasis driven by ZEB1, human lung carcinoma cells, and human breast carcinoma cells. Transcriptional profiling studies revealed that ZEB1 controls the expression of numerous oncogenic and tumor-suppressive miRs, including miR-34a. Ectopic expression of miR-34a decreased tumor cell invasion and metastasis, inhibited the formation of promigratory cytoskeletal structures, suppressed activation of the RHO GTPase family, and regulated a gene expression signature enriched in cytoskeletal functions and predictive of outcome in human lung adenocarcinomas. We identified several miR-34a target genes, including Arhgap1, which encodes a RHO GTPase activating protein that was required for tumor cell invasion. These findings demonstrate that ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression and provide a compelling rationale to develop miR-34a as a therapeutic agent in lung cancer patients.
Keywords: Cells, Cultured; Cell Line, Tumor; Animals; Humans; Mice; Adenocarcinoma; Lung Neoplasms; Doxycycline; rho GTP-Binding Proteins; Luciferases; Transforming Growth Factor beta; Homeodomain Proteins; Tumor Suppressor Proteins; Transcription Factors; MicroRNAs; Oligonucleotide Array Sequence Analysis; Cell Separation; Statistics, Nonparametric; Neoplasm Transplantation; Signal Transduction; Cell Proliferation; Cell Movement; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, Reporter; Promoter Regions, Genetic; Mice, 129 Strain; Epithelial-Mesenchymal Transition; Actin Cytoskeleton; Transcriptome; Zinc Finger E-box-Binding Homeobox 1
Rights: Copyright © 2012, American Society for Clinical Investigation
RMID: 0020122196
DOI: 10.1172/JCI63608
Grant ID:
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_74830.pdfPublished version5.07 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.